CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Darunavir and CobicistatWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)


Name (Synonyms) Correlation

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D011020 Pneumonia, Pneumocystis NIH 0.71
D011014 Pneumonia NIH 0.08

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.15

There is one clinical trial.

Clinical Trials


1 Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19

The study aims to evaluate the efficacy and safety of darunavir and cobistastat in the treatment of COVID-19 pneumonia

NCT04252274 Pneumonia, Pneumocystis Coronavirus Drug: Darunavir and Cobicistat
MeSH:Pneumonia, Pneumocystis Pneumonia
HPO:Pneumonia

Primary Outcomes

Measure: The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7

Time: 7 days after randomization

Secondary Outcomes

Measure: The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3

Time: 3 days after randomization

Measure: The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 5

Time: 5 days after randomization

Measure: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

Time: 14 days after randomization

Description: The diagnosis of critical illness case was based on the notice on printing and distributing the diagnosis and treatment plan of pneumonia with new coronavirus infection (trial version 4) made by National Health Commission of the People's Republic of China.

Measure: The critical illness rate of subjects at weeks 2

Time: 14 days after randomization

Measure: The mortality rate of subjects at weeks 2

Time: 14 days after randomization


Related HPO nodes (Using clinical trials)